EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MDR1 Inhibition Reverses Doxorubicin-Resistance in Six Doxorubicin-Resistant Canine Prostate and Bladder Cancer Cell Lines

Eva-Maria Packeiser iD, Leoni Engels, Ingo Nolte, Sandra Goericke-Pesch iD, Hugo Murua Escobar iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24098136 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Eva-Maria Packeiser und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover, Foundation, 30559 Hannover, Germany. Hauptthemen laut MEDLINE: Prostate, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acquired chemoresistance during chemotherapy, often accompanied by cross- and multi-resistance, limits therapeutic outcomes and leads to recurrence. In order to create in vitro model systems to understand acquired doxorubicin-resistance, we generated doxorubicin-resistant sublines of canine prostate adenocarcinoma and urothelial cell carcinoma cell lines. Chemoresistance to doxorubicin, cross-resistance to carboplatin, and the reversibility of the acquired resistance by the specific MDR1-inhibitor tariquidar were quantified in metabolic assays. Resistance mechanisms were characterized by expression of the efflux transporters MDR1 and RALBP1, as well as the molecular target of doxorubicin, TOP2A, with qPCR and Western blotting. Six out of nine cell lines established stable resistance to 2 µM doxorubicin. Drug efflux via massive MDR1 overexpression was identified as common, driving resistance mechanism in all sublines. MDR1 inhibition with tariquidar extensively reduced or reversed the acquired, and also partly the parental resistance. Three cell lines developed additional, non-MDR1-dependent resistance. RALBP1 was upregulated in one resistant subline at the protein level, while TOP2A expression was not altered. Combination therapies aiming to inhibit MDR1 activity can now be screened for synergistic effects using our resistant sublines. Nevertheless, detailed resistance mechanisms and maintained molecular target expression in the resistant sublines are still to be examined.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProstateUrinary Bladder NeoplasmsMaleAnimalsDogsATP Binding Cassette Transporter, Subfamily B, Member 1DoxorubicinCell LineDrug Resistance, NeoplasmCell Line, Tumor

Stichwörter der Autor:innen

ABCB1MDR1bladder cancercell linechemoresistancedogdoxorubicinprostate cancer

Substanzen

ATP Binding Cassette Transporter, Subfamily B, Member 1Doxorubicin

Autor:innen und Institutionen

  • Department of Small Animal Medicine and Surgery, University of Veterinary Medicine Hannover, Foundation, 30559 Hannover, Germany.
  • Unit for Reproductive Medicine-Clinic for Small Animals, University of Veterinary Medicine Hannover, Foundation, 30559 Hannover, Germany.
  • Department of Medicine, Clinic III, Hematology, Oncology and Palliative Medicine, University Medical Center Rostock, 18057 Rostock, Germany.

ORCID-Profile: Eva-Maria Packeiser, Sandra Goericke-Pesch, Hugo Murua Escobar

Zitieren

APA

Packeiser, E. M., Engels, L., Nolte, I., Goericke-Pesch, S., & Murua Escobar, H. (2023). MDR1 Inhibition Reverses Doxorubicin-Resistance in Six Doxorubicin-Resistant Canine Prostate and Bladder Cancer Cell Lines. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24098136

Vancouver

Packeiser EM, Engels L, Nolte I, Goericke-Pesch S, Murua Escobar H. MDR1 Inhibition Reverses Doxorubicin-Resistance in Six Doxorubicin-Resistant Canine Prostate and Bladder Cancer Cell Lines. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24098136

BibTeX
@article{Packeiser2023,
  author = {Packeiser, Eva-Maria and Engels, Leoni and Nolte, Ingo and Goericke-Pesch, Sandra and Murua Escobar, Hugo},
  title = {MDR1 Inhibition Reverses Doxorubicin-Resistance in Six Doxorubicin-Resistant Canine Prostate and Bladder Cancer Cell Lines},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24098136}
}
Kostenlos starten →